Guidelines for the treatment of psoriatic arthritis with biologics
Guidelines for the treatment of psoriatic arthritis with biologics
Guidelines for the treatment of psoriatic arthritis with biologics
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
16 Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab <strong>for</strong> <strong>the</strong> <strong>treatment</strong> <strong>of</strong> patients <strong>with</strong> moderately<br />
to severely active <strong>psoriatic</strong> <strong>arthritis</strong>: results <strong>of</strong> a double‐blind, randomized, placebo‐controlled trial. Arthritis<br />
Rheum 2005;52(10):3279‐89.<br />
17 Sterry W, Ortonne JP, Kirkham B, et al. Comparison <strong>of</strong> two etanercept regimens <strong>for</strong> <strong>treatment</strong> <strong>of</strong><br />
psoriasis and <strong>psoriatic</strong> <strong>arthritis</strong>: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147.<br />
18 Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance <strong>the</strong>rapy <strong>for</strong> moderate‐tosevere<br />
psoriasis: a phase III, multicentre, double‐blind trial. Lancet 2005;366(9494):1367‐74.<br />
19 Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha<br />
antibody, administered every four weeks as a subcutaneous injection in <strong>psoriatic</strong> <strong>arthritis</strong>: Twenty‐four‐week<br />
efficacy and safety results <strong>of</strong> a randomized, placebo‐controlled study. Arthritis Rheum 2009;60(4):976‐86.<br />
20 Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation <strong>of</strong> <strong>the</strong> efficacy and safety <strong>of</strong> infliximab on<br />
<strong>psoriatic</strong> nails: an unblinded, nonrandomized, open‐label study. The British journal <strong>of</strong> dermatology<br />
2008;159(2):453‐6.<br />
21 Van den Bosch F, Manger B, Goupille P, et al. Effectiveness <strong>of</strong> adalimumab in treating patients <strong>with</strong><br />
active <strong>psoriatic</strong> <strong>arthritis</strong> and predictors <strong>of</strong> good clinical responses <strong>for</strong> <strong>arthritis</strong>, skin and nail lesions. Ann Rheum<br />
Dis 2010;69(2):394‐9.<br />
22 Braun J, van den Berg R, Baraliakos X, et al. 2010 update <strong>of</strong> <strong>the</strong> ASAS/EULAR recommendations <strong>for</strong> <strong>the</strong><br />
management <strong>of</strong> ankylosing spondylitis. Ann Rheum Dis 2011;70(6):896‐904.<br />
23 Keat A, Barkham N, Bhalla A, et al. BSR guidelines <strong>for</strong> prescribing TNF‐alpha blockers in adults <strong>with</strong><br />
ankylosing spondylitis. Report <strong>of</strong> a working party <strong>of</strong> <strong>the</strong> British Society <strong>for</strong> Rheumatology. Rheumatology<br />
(Ox<strong>for</strong>d) 2005;44(7):939‐47.<br />
24 van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update <strong>of</strong> <strong>the</strong> international ASAS<br />
recommendations <strong>for</strong> <strong>the</strong> use <strong>of</strong> anti‐TNF agents in patients <strong>with</strong> axial spondylo<strong>arthritis</strong>. Ann Rheum Dis<br />
2011;70(6):905‐8.<br />
25 Kristensen LE, Geborek P, Saxne T. Dose escalation <strong>of</strong> infliximab <strong>the</strong>rapy in <strong>arthritis</strong> patients is related<br />
to diagnosis and concomitant methotrexate <strong>treatment</strong>: observational results from <strong>the</strong> South Swedish Arthritis<br />
Treatment Group register. Rheumatology (Ox<strong>for</strong>d) 2009;48(3):243‐5.<br />
26 Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability <strong>of</strong> anti‐tumour necrosis factor<br />
<strong>the</strong>rapy in <strong>psoriatic</strong> <strong>arthritis</strong> patients: results from <strong>the</strong> South Swedish Arthritis Treatment Group register. Ann<br />
Rheum Dis 2008;67(3):364‐9.<br />
27 Spadaro A, Ceccarelli F, Scrivo R, Valesini G. Life‐table analysis <strong>of</strong> etanercept <strong>with</strong> or <strong>with</strong>out<br />
methotrexate in patients <strong>with</strong> <strong>psoriatic</strong> <strong>arthritis</strong>. Ann Rheum Dis 2008;67(11):1650‐1.<br />
28 Saad AA, Ashcr<strong>of</strong>t DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL. Efficacy and safety <strong>of</strong> anti‐TNF<br />
<strong>the</strong>rapies in <strong>psoriatic</strong> <strong>arthritis</strong>: an observational study from <strong>the</strong> British Society <strong>for</strong> Rheumatology Biologics<br />
Register. Rheumatology (Ox<strong>for</strong>d) 2010.<br />
29 D'Angelo S, Cutro MS, Lubrano E, et al. Combination <strong>the</strong>rapy <strong>with</strong> ciclosporin and etanercept in<br />
patients <strong>with</strong> <strong>psoriatic</strong> <strong>arthritis</strong>. Ann Rheum Dis 2010;69(5):934‐5.<br />
30 Eberl G, Studnicka‐Benke A, Hitzelhammer H, Gschnait F, Smolen JS. Development <strong>of</strong> a disease activity<br />
index <strong>for</strong> <strong>the</strong> assessment <strong>of</strong> reactive <strong>arthritis</strong> (DAREA). Rheumatology (Ox<strong>for</strong>d) 2000;39(2):148‐55.<br />
21
Change language